- 15 November 2017
Xeltis today announced the completion of an oversubscribed €45 Million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurma Partners and VI Partners) also participated in the financing.
This is the largest investment round for a private medical device company in Europe in 2017, Xeltis says. The Series C financing will support continuation of clinical activities and acceleration of product and market development for the company’s novel aortic and pulmonary valve programs.
“This robust financing provides us with the resources necessary to catapult our strategy forward – supporting a quick expansion of our aortic and pulmonary valve programs and strengthening our quest to redefine heart valve replacement therapy,” said Xeltis Chief Executive Officer (CEO) Laurent Grandidier.